OncLive: ADCs emerge as exciting addition to ovarian cancer treatment
A class of drugs called antibody-drug coagulates (ADC) are designed with a specific target within the tumors that are not present within normal tissue. This targeted approach helps kill tumor cells while sparing healthy cells.
In late 2022, the FDA approved a new ADC called Mirvetuximab Soravtansine-gynx to treat certain types of ovarian cancer. Caroline Billingsley, MD, University of Cincinnati Cancer Center physician and associate professor in UC's College of Medicine, participated in a Q&A with publication OncLive to discuss the current state and future of ADCs in ovarian cancer treatment.
Billingsley said the FDA approval "gives us an exciting option for patients who have already seen a lot of chemotherapy and [experienced] a lot of toxicity.
"This is a drug that we can offer that [has more] limited toxicity and [exhibits] some efficacy. It’s an exciting time to adopt this drug into our treatment lines,” she continued.
Ongoing studies are researching Mirvetuximab Soravtansine-gynx as both a monotherapy and in combination with other treatments, Billingsley said.
"Given that it has a favorable toxicity profile, it’s an ideal drug to combine with other agents," she said.
Featured photo at top of ovarian cancer tumor in animal model courtesy of National Cancer Institute.
Related Stories
CCM welcomes new film and media scoring faculty member J.R. Paredes
May 20, 2026
UC College-Conservatory of Music Dean Pete Jutras has announced the appointment of J.R. Paredes as CCM's new Assistant Professor of Film and Media Scoring. His faculty appointment officially begins on Aug. 15, 2026. Paredes is a composer, music producer and audio post-production specialist whose work spans film, television and commercial music. His credits include original scores for feature films and series distributed on platforms such as Apple TV+ and Prime Video, as well as extensive work in sound design and mixing for film and media.
6 ways starting a GLP-1 medication could affect your emotions
May 20, 2026
When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.